GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » 3-Year Book Growth Rate

Cannara Biotech (TSXV:LOVE) 3-Year Book Growth Rate : 19.30% (As of Feb. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech 3-Year Book Growth Rate?

Cannara Biotech's Book Value per Share for the quarter that ended in Feb. 2024 was C$0.88.

During the past 12 months, Cannara Biotech's average Book Value per Share Growth Rate was 11.20% per year. During the past 3 years, the average Book Value per Share Growth Rate was 19.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was 25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Cannara Biotech was 51.10% per year. The lowest was 4.50% per year. And the median was 19.30% per year.


Competitive Comparison of Cannara Biotech's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's 3-Year Book Growth Rate falls into.



Cannara Biotech 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.


Cannara Biotech  (TSXV:LOVE) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.


Cannara Biotech 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech (TSXV:LOVE) Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director

Cannara Biotech (TSXV:LOVE) Headlines

From GuruFocus

LOVESAC INVESTOR DEADLINE APPROACHING

By PRNewswire 01-04-2024